The Proportion Cured of Patients with Resected Stage II-III Cutaneous Melanoma in Sweden.
cure proportions
median survival times
stage II–III melanoma
survival ratios
uncured patients
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
18 May 2021
18 May 2021
Historique:
received:
26
03
2021
revised:
12
05
2021
accepted:
14
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Cure proportion represents the proportion of patients who experience the same mortality rate as the general population and can be estimated together with the survival of the proportion experiencing excess mortality (the uncured). The aim was to estimate the cure proportions and survival among uncured stage II-III cutaneous melanoma (CM) patients. 1- and 5-year relative survival ratios, cure proportions and the median survival times of uncured stage II-III CM patients in Sweden ( Stages IIB and IIC showed significant differences in standardized cure proportions vs. stage IIA CM (0.80 (95% CI 0.77-0.83) stage IIA; 0.62 (95% CI 0.59-0.66) stage IIB; 0.42 (95% CI 0.37-0.46) for stage IIC). Significant differences in standardized cure proportions were found for stages IIIB and IIIC-D CM vs. stage IIIA (0.76 (95% CI 0.68-0.84) stage IIIA; 0.52 (95% CI 0.45-0.59) stage IIIB; 0.35 (95% CI 0.30-0.39) for stage IIIC-D). The results are emphasizing the poor prognosis with low proportions cured by surgery only for sub-groups of stage II-III CM, specifically within stages IIB-C CM.
Sections du résumé
BACKGROUND
BACKGROUND
Cure proportion represents the proportion of patients who experience the same mortality rate as the general population and can be estimated together with the survival of the proportion experiencing excess mortality (the uncured). The aim was to estimate the cure proportions and survival among uncured stage II-III cutaneous melanoma (CM) patients.
METHODS
METHODS
1- and 5-year relative survival ratios, cure proportions and the median survival times of uncured stage II-III CM patients in Sweden (
RESULTS
RESULTS
Stages IIB and IIC showed significant differences in standardized cure proportions vs. stage IIA CM (0.80 (95% CI 0.77-0.83) stage IIA; 0.62 (95% CI 0.59-0.66) stage IIB; 0.42 (95% CI 0.37-0.46) for stage IIC). Significant differences in standardized cure proportions were found for stages IIIB and IIIC-D CM vs. stage IIIA (0.76 (95% CI 0.68-0.84) stage IIIA; 0.52 (95% CI 0.45-0.59) stage IIIB; 0.35 (95% CI 0.30-0.39) for stage IIIC-D).
CONCLUSIONS
CONCLUSIONS
The results are emphasizing the poor prognosis with low proportions cured by surgery only for sub-groups of stage II-III CM, specifically within stages IIB-C CM.
Identifiants
pubmed: 34070092
pii: cancers13102456
doi: 10.3390/cancers13102456
pmc: PMC8158378
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Swedish Cancer Society
ID : 190278Fk01H
Organisme : the Cancer Research Foundations of Radiumhemmet
ID : 181083
Organisme : the Swedish Medical Society
ID : SLS-934511, SLS-961466
Organisme : the Swedish Society for Medical Research
ID : 2017
Organisme : KI Funds
ID : FS-2020:0007
Organisme : Region Stockholm
ID : 2021-01
Organisme : Hudfonden
ID : 4-1880/2020
Organisme : the Sigurd and Elsa Golje Memorial Fund
ID : LA-2020-0148
Organisme : Folkfonden
ID : 2929
Références
Lancet Oncol. 2018 Feb;19(2):181-193
pubmed: 29361468
JAMA Dermatol. 2019 Jun 1;155(6):688-693
pubmed: 31042258
J Clin Oncol. 2012 Jun 20;30(18):2240-7
pubmed: 22547594
Ann Surg Oncol. 2019 Sep;26(9):2839-2845
pubmed: 31111349
J Clin Oncol. 2013 Jun 20;31(18):2337-46
pubmed: 23690423
J Clin Oncol. 2020 Nov 20;38(33):3925-3936
pubmed: 32946353
Stat Med. 2007 Dec 30;26(30):5486-98
pubmed: 17893893
N Engl J Med. 2018 May 10;378(19):1789-1801
pubmed: 29658430
J Clin Oncol. 2020 Aug 1;38(22):2543-2551
pubmed: 32530760
Ann Surg. 2006 May;243(5):693-8; discussion 698-700
pubmed: 16633005
Int J Cancer. 2016 Jun 15;138(12):2829-36
pubmed: 26815934
Ann Surg Oncol. 2018 Aug;25(8):2105-2110
pubmed: 29850954
Arch Dermatol. 2005 Jun;141(6):745-50
pubmed: 15967921
Nat Med. 2021 Feb;27(2):256-263
pubmed: 33558721
BMC Med Res Methodol. 2011 Jun 22;11:96
pubmed: 21696598
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
N Engl J Med. 2017 Nov 9;377(19):1824-1835
pubmed: 28891423
N Engl J Med. 2017 Nov 9;377(19):1813-1823
pubmed: 28891408
Lancet Oncol. 2020 Nov;21(11):1465-1477
pubmed: 32961119
Lancet Oncol. 2019 Jul;20(7):948-960
pubmed: 31160251
Cancer Epidemiol. 2014 Feb;38(1):93-9
pubmed: 24447700
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155
Ann Surg Oncol. 2017 Apr;24(4):939-946
pubmed: 27804026
J Clin Oncol. 2018 Dec 10;36(35):3441-3449
pubmed: 30343620
CA Cancer J Clin. 2017 Nov;67(6):472-492
pubmed: 29028110
Int J Epidemiol. 2015 Oct;44(5):1549-56
pubmed: 26108436
J Oncol. 2012;2012:647684
pubmed: 22792102
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Clin Oncol. 2009 Dec 20;27(36):6199-206
pubmed: 19917835